Back

EORTC 55955

Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial.

Date of Publication:

October 2, 2010

Pubmed Link:
https://www.ncbi.nlm.nih.gov/pubmed/20888993
Hypothesis:

Is there benefit of early treatment of relapsed ovarian cancer on the basis of increased serum CA125 concentrations compared with delayed treatment on the basis of clinical recurrence?

Control Arm(s):

Exam, imaging, CA125 every 3 months

Once CA125 increased to 2x upper limit of normal - clinical evaluation until recurrence clinically detected

Experimental Arm(s):

Exam, imaging, CA125 every 3 months

Once CA125 increased to 2x upper limit of normal - chemotherapy started

Primary End Point:

OS

Inclusion Criteria:

epithelial ovarian cancer cancer

Complete clinical remission after completion of first-line platinum-based chemotherapy

Normal CA125

Exclusion Criteria:
Results:

Early vs Delayed Treatment:

median f/u: 56.9 mos

Median OS: 25.7  vs 27.1 mos (NS)

Require third-line chemotherapy: 67% vs 54% (SS)

Time to third-line chemotherapy: 12.5  vs 17.1 mos (SS)

Conclusions:

Early initiation of chemotherapy, at the time of rising CA-125, does not improve OS compared with delayed treatment in women with epithelial ovarian cancer in complete remission after completion of first-line chemotherapy.

Reviewer:
Mona Guo, OTF